In PLoS One this week, MIT researchers say they've developed the first ever broad-spectrum antiviral therapeutic. Instead of taking a pathogen-specific approach to developing antivirals, the team has created a new approach, called Double-Stranded RNA Activated Caspase Oligomerizer, or DRACO, which selectively induces apoptosis in cells that contain viral dsRNA, and kills infected cells without harming normal cells.